Analysis of the correlation between neuroimaging markers of the brain damage and the severity of postural instability in patients with chronic cerebrovascular insufficiency (NEMAN open observational study)

Samartcev I.N.

Kirov Military Medical Academy

SPIN RSCI: 9857-4986
Scopus AuthorID: 57218542945
ORCID: 0000-0002-7659-9756

Zhivolupov S.A.

Kirov Military Medical Academy

Efimtsev A.Yu.

Almazov National Medical Research Center

Ponomarev V.V.

Belarusian Medical Academy of Postgraduate Education

Analysis of the correlation between neuroimaging markers of the brain damage and the severity of postural instability in patients with chronic cerebrovascular insufficiency (NEMAN open observational study)

Authors:

Samartcev I.N., Zhivolupov S.A., Efimtsev A.Yu., Ponomarev V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7): 66‑73

DOI: 10.17116/jnevro202212207166

Downloaded: 39

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Samartcev IN, Zhivolupov SA, Efimtsev AYu, Ponomarev VV. Analysis of the correlation between neuroimaging markers of the brain damage and the severity of postural instability in patients with chronic cerebrovascular insufficiency (NEMAN open observational study). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7):66‑73. (In Russ.)
https://doi.org/10.17116/jnevro202212207166

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)

Close metadata

OBJECTIVE

To analyze the relationship between the severity of postural instability in patients with CCI (chronic cerebral ischemia) and brain changes according to MRI, as well as to evaluate the efficacy and safety of vinpocetine.

MATERIAL AND METHODS

The study included 60 patients with CCI: 40 people with postural instability made up the main group and 20 people without balance disorders — the control group. The severity of manifestations of cerebrovascular pathology was assessed according to the protocol STRIVE. Severity of postural instability was assessed with the VAS, anxiety syndrome — Hamilton Anxiety Rating Scale, asthenia — Asthenic Condition Scale, daytime sleepiness — Epworth Sleepiness Scale, cognitive impairment — Montreal scale assessment of cognitive functions, the overall impression of treatment — Global Rating of Change Scale.

RESULTS

The main group was associated with older age, more significant decrease in cognitive functions, urination disorders, anxiety syndrome and asthenia, changes according to MRI of the brain. CCI burden scale was significantly associated with VAS: β=0.479, P=0.035, 95% CI 0.023—0.928. The presence of lacunae was the most significant marker for the development of severe imbalance: β=0.482, p=0.041, 95% CI 0.022—0.925. A significant relationship was found between the total number of lacunae and VAS (r=0.509, p=0.021), as well as between the number of lacunae in the basal ganglia (r=0.793, p=0.019), especially the lenticular nuclei (r=0.498, p=0.036), and VAS. After 3 months of vinpocetine treatment, a significant improvement in statodynamic function was noted in the main group, moreover — absence of anxiety, normalization of daytime sleep, «weak» asthenia, increasement in the value of the MoCA scale. Most of the patients regarded the improvement from the therapy as «moderate» and «pronounced».

CONCLUSIONS

The presence of lacunes in the basal ganglia is a most prominent neuroimaging marker of brain damage in patients with CCI and postural instability. The use of vinpocetine can significantly reduce the severity of imbalance, anxiety and asthenia, and normalize the circadian rhythm of sleep.

Keywords:

chronic cerebrovascular insufficiency

postural instability

neuroimaging markers

vinpocetine

Authors:

Samartcev I.N.

Kirov Military Medical Academy

SPIN RSCI: 9857-4986
Scopus AuthorID: 57218542945
ORCID: 0000-0002-7659-9756

Zhivolupov S.A.

Kirov Military Medical Academy

Efimtsev A.Yu.

Almazov National Medical Research Center

Ponomarev V.V.

Belarusian Medical Academy of Postgraduate Education

Received:

24.05.2022

Accepted:

07.06.2022

List of references:

Litvinenko IV. Parkinson’s disease. M.: Miklosh; 2006;216. (In Russ.).
Barin K, Dodson EE. Dizziness in the elderly. Otolaryngol Clin North Am. 2011;44(2):437-454. https://doi.org/10.1016/j.otc.2011.01.013
Vaz Garcia F. Disequilibrium and its management in elderly patients. Int Tinnitus J. 2009;15(1):83-90.
World Health Organization, 2016. Falls. https://wwww.who.int/mediacentre/factsheets/fs344
Mueller M, Strobl R, Jahn K, et al. Burden of disability attributable to vertigo and dizziness in the aged: KORA-Age study. Eur J Public Health. 2014;24(5):802-807. https://doi.org/10.1093/eurpub/ckt171
Suzuki K, Fujita H, Matsubara T. Non-motor symptoms in postural instability/gait difficulty disease. Eur J Neurol. 2019;26(3):37-43.
Ter Telgte A, van Leijsen EMC, Wiegertjes K, et al. Cerebral small vessel disease: from a focal to a global perspective. Nat Rev Neurol. 2018;14(7):387-398. https://doi.org/10.1038/s41582-018-0014-y
Levin OS, Yunischenko NA, Skvortsov DV. Clinical and instrumental analysis of walking and postural instability in Parkinson’s disease. In: Modern technologies of restorative medicine: Proceedings of the VII Intern. conf. Sochi. 2004;388-390. (In Russ.).
Fujita H, Kasubuchi K, Wakata S, et al. Role of the Frontal Cortex in Standing Postural Sway Tasks While Dual-Tasking: A Functional Near-Infrared Spectroscopy Study Examining Working Memory Capacity. Biomed Res Int. 2016;2016:7053867. https://doi.org/10.1155/2016/7053867
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS, Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129-2170.
Zhivolupov SA, Samartsev IN, Yakovlev EV, et al. The effectiveness of Vinpocetine (Cavinton Comfort) in the treatment of dizziness in patients with dyscirculatory encephalopathy and its effect on the concentration of brain neurotrophic factor (BDNF) in plasma. Klinicheskaya Farmakologiya i Terapiya. 2016;(1):48-53. (In Russ.).
Samartsev IN, Zhivolupov SA, Butakova YS, et al. Efficiency of long-term vinpocetine administration in the treatment of dizziness and associated statodynamic disorders in patients with chronic cerebrovascular insufficiency (EDELWEISS study). Neurology Neuropsychiatry Psychosomatics. 2019;11(1):36-47. (In Russ.).
Wardlaw JM, Smith EE, Biessels GJ, et al. nEuroimaging STfRVco. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838. https://doi.org/10.1016/S1474-4422(13)70124-8
Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43(9):1683-1689. https://doi.org/10.1212/wnl.43.9.1683
Doubal FN, MacLullich AM, Ferguson KJ, et al. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke. 2010;41(3):450-454. https://doi.org/10.1161/STROKEAHA.109.564914
Lau KK, Li L, Schulz U, et al. Total small vessel disease score and risk of recurrent stroke: validation in 2 large cohorts. Neurology. 2017;88(24):2260-2267. https://doi.org/10.1212/WNL.0000000000004042
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;4:540-545.
Handbook of a practical psychologist. Tutorial. M.: VLADOS; 1999. (In Russ.).
Jaeschke R, Singer J, Guyatt G. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407-415. https://doi.org/10.1016/0197-2456(89)90005-6
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A Screening Tool Mild Cognitive Impairment. J Am Geriatr Soc. 2005;53(4):695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
Rebrova OS. Statistichesky analis meditsinskikh dannykh. Primenenije paketa prikladnykh program Statistica. M.: MediaSfera; 2002;312. (In Russ.).
Smith EE, O’Donnell M, Dagenais G, et al. and PURE Investigators. Early cerebral small vessel disease and brain volume, cognition, and gait. Ann Neurol. 2015;77:251-261.
Reijmer YD, Fotiadis P, Martinez-Ramirez S, et al. Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy. Brain. 2015;138:179-188.
Zotin Z, Sveikata CM, Lukasa A, et al. Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management. Curr Op Neurol. 2021;34(2):246-257. https://doi.org/10.1097/WCO.0000000000000913
Benisty S, Gouw AA, Porcher R. Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. J Neurol Neurosurg Psychiatry. 2009;80:478-483.
Lee J, Choi JC, Kang S, et al. Effects of lacunar infarctions on cognitive impairment in patients with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Clin Neurol (Seoul, Korea). 2011;7:210-214.
Chen H, Zhang M, Liu G, et al. Effect of small vessel disease burden and lacunes on gait/posture impairment in Parkinson’s disease. Neurol Sci. 2020;41(12):3617-3624. https://doi.org/10.1007/s10072-020-04452-z
Nutt J, Bloem B, Giladi N, et al. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol. 2011;10:734-744. https://doi.org/10.1016/s1474-4422(11)70143-0
Gulyás B, Tóth M, Schain M, et al. Evolution of microglial activation in ischaemic core and peri-infarct regions after stroke: A PET study with the TSPO molecular imaging biomarker [11C] vinpocetine. J Neurol Sci. 2012;320:110-117.
Skoromets AA, Aliev KT, Lalayan TV, et al. Cognitive functions and treatment of their impairment in elderly patients with the vertebrobasilar issufficiensy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013;113(4):18-24. (In Russ.).
Tabeeva GR, Kalimeeva EYu, Koberskaya NN, Gereeva SI. Possibilities of therapy for early manifestations of chronic cerebral ischemia: results of the PROFILE program. Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(3):36-41. (In Russ.). https://doi.org/10.14412/2074-2711-2017-3-36-41
Vakhnina NV, Milovanova OV. Neurological disorders in patients with hypertension and their correction. Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(4):32-37. (In Russ.). https://doi.org/10.14412/2074-2711-2016-4-32-37
Shavlovskaya OA, Lokshina AB, Grishina DA. Cavinton comforte in correcting cognitive impairment in chronic brain ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(8):61-65. (In Russ.). https://doi.org/10.17116/jnevro201811808161
Chukanova EI, Nikonov AA, Nikonova AA. New uses of the drug Cavinton in the treatment of patients with cerebrovascular insufficiency. RMZH. 2009;12(11):751-756. (In Russ.).
Szatmari S, Whitehouse P. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;(1):CD003119.

Close metadata